<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Chemical Sedation - Haldoperidol vs. Lorazepam vs. Midazolam</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->3/25/2011</div></div><div class="card__content"><h1 id="chemical-sedation-haldoperidol-vs-lorazepam-vs-midazolam">Chemical Sedation: Haldoperidol vs. Lorazepam vs. Midazolam</h1>
<h2 id="question">Question</h2>
<p>What single agent best manages violent, agitated patients in the ED, as measured by shortest time to sedation and shortest time to arousal?</p>
<h2 id="methodology">Methodology</h2>
<ul>
<li>Prospective, randomized, double-blinded study of 111 violent and agitated patients</li>
<li><span class="drug">Haloperidol<span> (5 mg IM), <span class="drug">Lorazepam</span> (2 mg IM), or <span class="drug">Midazolam</span> (5 mg IM)</li>
<li><span class="drug">Midazolam</span> is a water-soluble benzodiazepine – excellent IM absorption profile</li>
<li>Patients were agitated because of recreational drug use, alcohol use, and prior psychiatric history and divided equally in each of the 3 arms of treatment.</li>
</ul>
<h2 id="results">Results</h2>
<p>|                        | Haloperidol (n=42) | Lorazepam (n=27) | Midazolam (n=42) |
| ---------------------- | :----------------: | :--------------: | :--------------: |
| Time to sedation (min) |      28.3 ± 25     |     32.3 ± 20    |     18.3 ± 14    |
| Time to arousal (min)  |     126.5 ± 85     |    217.2 ± 107   |     81.9 ± 66    |</p>
<p>There were <strong>no significant differences in vital signs</strong> between groups.</p>
<p>Lorazepam was stopped after the first 95 patients at interim analysis because of prolonged sedation times.</p>
<p>Patients required “rescue drugs”, which were additional sedation medications at the discretion of attending physician: </p>
<ul>
<li>8 <span class="drug">haloperidol</span> patients (19%)</li>
<li>7 <span class="drug">lorazepam</span> patients (26%) </li>
<li>7 <span class="drug">midazolam</span> patients (17%)</li>
</ul>
<p><strong>Complications:</strong> 2 patients who received haloperidol</p>
<ul>
<li>1 had hypotension</li>
<li>1 had transient apnea</li>
</ul>
<h2 id="other-im-medication-options">Other IM medication options</h2>
<ul>
<li><em>HAC:</em> <span class="drug">Haloperidol</span> 5 mg, <span class="drug">Ativan (lorazepam)</span> 2 mg, <span class="drug">Cogentin</span> 1 mg IM all in 1 syringe</li>
<li><em>B52:</em> <span class="drug">Haloperidol</span> 5 mg, <span class="drug">Lorazepam</span> 2 mg, <span class="drug">Benedryl (diphenhydramine)</span> 50 mg IM</li>
</ul>
<h2 id="bottom-line">BOTTOM LINE</h2>
<ul>
<li>Use <strong><span class="drug">midazolam</span> 5 mg IM</strong> to chemically sedation a severely agitated patients because of its <strong>shorter time to sedation</strong> (18 min) and <strong>arousal</strong> (82 min).</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li>Nobay F et al. A Prospective, Double-blind, Randomized Trial of Midazolam versus Haloperidol versus Lorazepam in the Chemical Restraint of Violent and Severely Agitated Patients . Acad Emerg Med. 2004; 11:747-9. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15231461">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"chemical-sedation","title":"Chemical Sedation - Haldoperidol vs. Lorazepam vs. Midazolam","authors":["Michelle Lin, MD"],"categories":[{"slug":"pharmacology","name":"Pharmacology"}],"created":"2011/03/25","updated":null,"body":"\n# Chemical Sedation: Haldoperidol vs. Lorazepam vs. Midazolam\n\n## Question\n\nWhat single agent best manages violent, agitated patients in the ED, as measured by shortest time to sedation and shortest time to arousal?\n\n## Methodology\n\n- Prospective, randomized, double-blinded study of 111 violent and agitated patients\n- \u003cspan class=\"drug\"\u003eHaloperidol\u003cspan\u003e (5 mg IM), \u003cspan class=\"drug\"\u003eLorazepam\u003c/span\u003e (2 mg IM), or \u003cspan class=\"drug\"\u003eMidazolam\u003c/span\u003e (5 mg IM)\n- \u003cspan class=\"drug\"\u003eMidazolam\u003c/span\u003e is a water-soluble benzodiazepine – excellent IM absorption profile\n- Patients were agitated because of recreational drug use, alcohol use, and prior psychiatric history and divided equally in each of the 3 arms of treatment.\n\n## Results\n\n|                        | Haloperidol (n=42) | Lorazepam (n=27) | Midazolam (n=42) |\n| ---------------------- | :----------------: | :--------------: | :--------------: |\n| Time to sedation (min) |      28.3 ± 25     |     32.3 ± 20    |     18.3 ± 14    |\n| Time to arousal (min)  |     126.5 ± 85     |    217.2 ± 107   |     81.9 ± 66    |\n\nThere were **no significant differences in vital signs** between groups.\n\nLorazepam was stopped after the first 95 patients at interim analysis because of prolonged sedation times.\n\nPatients required “rescue drugs”, which were additional sedation medications at the discretion of attending physician: \n\n- 8 \u003cspan class=\"drug\"\u003ehaloperidol\u003c/span\u003e patients (19%)\n- 7 \u003cspan class=\"drug\"\u003elorazepam\u003c/span\u003e patients (26%) \n- 7 \u003cspan class=\"drug\"\u003emidazolam\u003c/span\u003e patients (17%)\n\n**Complications:** 2 patients who received haloperidol\n\n- 1 had hypotension\n- 1 had transient apnea\n\n## Other IM medication options\n\n- _HAC:_ \u003cspan class=\"drug\"\u003eHaloperidol\u003c/span\u003e 5 mg, \u003cspan class=\"drug\"\u003eAtivan (lorazepam)\u003c/span\u003e 2 mg, \u003cspan class=\"drug\"\u003eCogentin\u003c/span\u003e 1 mg IM all in 1 syringe\n- _B52:_ \u003cspan class=\"drug\"\u003eHaloperidol\u003c/span\u003e 5 mg, \u003cspan class=\"drug\"\u003eLorazepam\u003c/span\u003e 2 mg, \u003cspan class=\"drug\"\u003eBenedryl (diphenhydramine)\u003c/span\u003e 50 mg IM\n\n## BOTTOM LINE\n\n- Use **\u003cspan class=\"drug\"\u003emidazolam\u003c/span\u003e 5 mg IM** to chemically sedation a severely agitated patients because of its **shorter time to sedation** (18 min) and **arousal** (82 min).\n\n## References\n\n- Nobay F et al. A Prospective, Double-blind, Randomized Trial of Midazolam versus Haloperidol versus Lorazepam in the Chemical Restraint of Violent and Severely Agitated Patients . Acad Emerg Med. 2004; 11:747-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15231461)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"chemical-sedation"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>